Since its discovery in the 19th century, the complement system has developed into a clinically significant entity. The complement system has been implicated in a variety of clinical conditions, from autoimmune diseases to ischemia-reperfusion injury in transplantation. This article charts the historical progress of our understanding of the complement system and provides a synopsis on the activation pathways and its inherent regulators.
Schifferli JA et al.: The role of complement and its receptor in the elimination of immune complexes. N Engl J Med 315, 488–495 (1986)
Schifferli J.A. , 'The role of complement and its receptor in the elimination of immune complexes ' (1986 ) 315 N Engl J Med : 488 -495 .
Davies KA et al.: Complement deficiency and immune complex disease. Springer Semin Immunopathol 15, 397–416 (1994)
Davies K.A. , 'Complement deficiency and immune complex disease ' (1994 ) 15 Springer Semin Immunopathol : 397 -416 .
Mevorach D et al.: Complement-dependent clearance of apoptotic cells by human macrophages. J Exp Med 188, 2313–2320 (1998).
Mevorach D. , 'Complement-dependent clearance of apoptotic cells by human macrophages ' (1998 ) 188 J Exp Med : 2313 -2320 .
Tauber AI et al.: The birth of immunology. II. Metchnikoff and his critics. Cell Immunol 121, 447–473 (1989).
Tauber A.I. , 'The birth of immunology. II. Metchnikoff and his critics ' (1989 ) 121 Cell Immunol : 447 -473 .
Buchner H: Zur Nomenklatur der schutzenden Eiweisskorper. Centr Bakteriol Parasitenk 10, 699–701 (1891).
Buchner H. , 'Zur Nomenklatur der schutzenden Eiweisskorper ' (1891 ) 10 Centr Bakteriol Parasitenk : 699 -701 .
Skarnes RC et al.: Antimicrobial factors of normal tissues and fluids. Bacteriol Rev 21, 273–294 (1957).
Skarnes R.C. , 'Antimicrobial factors of normal tissues and fluids ' (1957 ) 21 Bacteriol Rev : 273 -294 .
Morgan BP: Complement: Clinical Aspects and Relevance to Disease. Academic Press, UK (1990).
Morgan B.P. , '', in Complement: Clinical Aspects and Relevance to Disease , (1990 ) -.
Kaufmann SH: Immunology’s foundation: the 100-year anniversary of the Nobel Prize to Paul Ehrlich and Elie Metchnikoff. Nat Immunol 9, 705–712 (2008).
Kaufmann S.H. , 'Immunology’s foundation: the 100-year anniversary of the Nobel Prize to Paul Ehrlich and Elie Metchnikoff ' (2008 ) 9 Nat Immunol : 705 -712 .
Ehrlich P et al.: Zur Theorie der Lysenwirkung [in German]. Berlin Klin Woch 36, 6 (1899).
Ehrlich P. , 'Zur Theorie der Lysenwirkung [in German] ' (1899 ) 36 Berlin Klin Woch : 6 -.
Witesbsky E: Ehrlich’s side-chain theory in the light of present immunology. Ann N Y Acad Sci 59, 168–181 (1954).
Witesbsky E. , 'Ehrlich’s side-chain theory in the light of present immunology ' (1954 ) 59 Ann N Y Acad Sci : 168 -181 .
Ferrata A: Berlin Klin Woch 44, 366 (1907).
Ferrata A. , '' (1907 ) 44 Berlin Klin Woch : 366 -.
Brand E: Berlin Klin Woch 46, 1075 (1907).
Brand E. , '' (1907 ) 46 Berlin Klin Woch : 1075 -.
Omorokow Z: Immunitätsforsh 10, 285 (1911).
Omorokow Z. , '' (1911 ) 10 Immunitätsforsh : 285 -.
Whitehead HR et al.: The “third component” or heat-stable factor of complement. Biochem J 19, 618–625 (1925).
Whitehead H.R. , 'The “third component” or heat-stable factor of complement ' (1925 ) 19 Biochem J : 618 -625 .
Coca AF: Z Immunitätsforsh 21, 604 (1914).
Coca A.F. , '' (1914 ) 21 Z Immunitätsforsh : 604 -.
Gordon J et al.: The fourth component of complement and its relation to opsonin. Biochem J 20, 1044–1045 (1926).
Gordon J. , 'The fourth component of complement and its relation to opsonin ' (1926 ) 20 Biochem J : 1044 -1045 .
Mayer MM: Development of the one-hit theory of immune hemolysis. Rutgers University Press, New Brunswick, NJ (1961).
Mayer M.M. , '', in Development of the one-hit theory of immune hemolysis , (1961 ) -.
Mayer MM et al.: A specific method for purification of the second component of guinea pig complement and a chemical evaluation of the one-hit theory. J Immunol 105, 327–341 (1970).
Mayer M.M. , 'A specific method for purification of the second component of guinea pig complement and a chemical evaluation of the one-hit theory ' (1970 ) 105 J Immunol : 327 -341 .
Inoue K et al.: Evidence for a one-hit theory in the immune bactericidal reaction and demonstration of a multi-hit response for hemolysis by streptolysin O and Clostridium perfringens theta-toxin. Infect Immun 13, 337–344 (1976).
Inoue K. , 'Evidence for a one-hit theory in the immune bactericidal reaction and demonstration of a multi-hit response for hemolysis by streptolysin O and Clostridium perfringens theta-toxin ' (1976 ) 13 Infect Immun : 337 -344 .
Morley BJ et al: The complement facts book. Academic Press, UK (2000).
Morley B.J. , '', in The complement facts book , (2000 ) -.
Mayer MM: Studies on the mechanism of hemolysis by antibody and complement. Prog Allergy 5, 215–270 (1958).
Mayer M.M. , 'Studies on the mechanism of hemolysis by antibody and complement ' (1958 ) 5 Prog Allergy : 215 -270 .
Muller-Eberhard H et al.: Isolation and description of the fourth component of human complement. J Exp Med 118, 447–466 (1963).
Muller-Eberhard H. , 'Isolation and description of the fourth component of human complement ' (1963 ) 118 J Exp Med : 447 -466 .
Nilsson UR et al.: Isolation of beta-IF from human serum and its characterizaion as the fifth component of the complement. J Exp Med 122, 277–298 (1965).
Nilsson U.R. , 'Isolation of beta-IF from human serum and its characterizaion as the fifth component of the complement ' (1965 ) 122 J Exp Med : 277 -298 .
Nilsson U: Separation and partial purification of the sixth, seventh and eighth components of human haemolytic complement. Acta Pathol Microbiol Scand 70, 469–480 (1967).
Nilsson U. , 'Separation and partial purification of the sixth, seventh and eighth components of human haemolytic complement ' (1967 ) 70 Acta Pathol Microbiol Scand : 469 -480 .
Manni JA et al.: The eighth component of human complement (C8): isolation, characterization, and hemolytic efficiency. J Exp Med 130, 1145–1160 (1969).
Manni J.A. , 'The eighth component of human complement (C8): isolation, characterization, and hemolytic efficiency ' (1969 ) 130 J Exp Med : 1145 -1160 .
Hadding U et al.: The ninth component of human complement: isolation, description and mode of action. Immunology 16, 719–735 (1969).
Hadding U. , 'The ninth component of human complement: isolation, description and mode of action ' (1969 ) 16 Immunology : 719 -735 .
Nelson RA Jr, et al.: Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum. Immunochemistry 3, 111–135 (1966).
Nelson R.A. , 'Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum ' (1966 ) 3 Immunochemistry : 111 -135 .
Nelson RA Jr, et al.: Complement components of a haemolytically deficient strain of rabbits. Immunology 14, 527–540 (1968).
Nelson R.A. , 'Complement components of a haemolytically deficient strain of rabbits ' (1968 ) 14 Immunology : 527 -540 .
Arumugam TV et al.: Complement mediators in ischemiareperfusion injury. Clin Chim Acta 374, 33–45 (2006).
Arumugam T.V. , 'Complement mediators in ischemiareperfusion injury ' (2006 ) 374 Clin Chim Acta : 33 -45 .
Morgan BP: Regulation of the complement membrane attack pathway. Crit Rev Immunol 19, 173–198 (1999).
Morgan B.P. , 'Regulation of the complement membrane attack pathway ' (1999 ) 19 Crit Rev Immunol : 173 -198 .
Barrington R et al.: The role of complement in inflammation and adaptive immunity. Immunol Rev 180, 5–15 (2001).
Barrington R. , 'The role of complement in inflammation and adaptive immunity ' (2001 ) 180 Immunol Rev : 5 -15 .
Gasque P: Complement: a unique innate immune sensor for danger signals. Mol Immunol 41, 1089–1098 (2004).
Gasque P. , 'Complement: a unique innate immune sensor for danger signals ' (2004 ) 41 Mol Immunol : 1089 -1098 .
Ehrnthaller C et al.: New insights of an old defense system: structure, function, and clinical relevance of the complement system. Mol Med 17, 317–329 (2011).
Ehrnthaller C. , 'New insights of an old defense system: structure, function, and clinical relevance of the complement system ' (2011 ) 17 Mol Med : 317 -329 .
Padilla ND et al.: Creactive protein and natural IgM antibodies are activators of complement in a rat model of intestinal ischemia and reperfusion. Surgery 142, 722–733 (2007).
Padilla N.D. , 'Creactive protein and natural IgM antibodies are activators of complement in a rat model of intestinal ischemia and reperfusion ' (2007 ) 142 Surgery : 722 -733 .
Pillemer L et al.: The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science 120, 279–285 (1954).
Pillemer L. , 'The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena ' (1954 ) 120 Science : 279 -285 .
Pillemer L: The properdin system. Trans N Y Acad Sci 17, 526–530 (1955).
Pillemer L. , 'The properdin system ' (1955 ) 17 Trans N Y Acad Sci : 526 -530 .
Pillemer L et al.: The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science 120, 279–285 (1954).
Pillemer L. , 'The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena ' (1954 ) 120 Science : 279 -285 .
Arumugam TV et al.: The role of the complement system in ischemia-reperfusion injury. Shock 21, 401–409 (2004).
Arumugam T.V. , 'The role of the complement system in ischemia-reperfusion injury ' (2004 ) 21 Shock : 401 -409 .
Thurman JM et al.: The central role of the alternative complement pathway in human disease. J Immunol 176, 1305–1310 (2006).
Thurman J.M. , 'The central role of the alternative complement pathway in human disease ' (2006 ) 176 J Immunol : 1305 -1310 .
Ganter MT et al.: Role of the alternative pathway in the early complement activation following major trauma. Shock 28, 29–34 (2007).
Ganter M.T. , 'Role of the alternative pathway in the early complement activation following major trauma ' (2007 ) 28 Shock : 29 -34 .
Diepenhorst GM et al.: Complement-mediated ischemia-reperfusion injury: lessons learned from animal and clinical studies. Ann Surg 249, 889–899 (2009).
Diepenhorst G.M. , 'Complement-mediated ischemia-reperfusion injury: lessons learned from animal and clinical studies ' (2009 ) 249 Ann Surg : 889 -899 .
Stahl GL et al.: Role for the alternative complement pathway in ischemia/reperfusion injury. Am J Pathol 162, 449–455 (2003).
Stahl G.L. , 'Role for the alternative complement pathway in ischemia/reperfusion injury ' (2003 ) 162 Am J Pathol : 449 -455 .
Kawasaki T et al.: Isolation and characterization of a mannan-binding protein from rabbit liver. Biochem Biophys Res Commun 81, 1018–1024 (1978).
Kawasaki T. , 'Isolation and characterization of a mannan-binding protein from rabbit liver ' (1978 ) 81 Biochem Biophys Res Commun : 1018 -1024 .
Kozutsumi Y et al.: Isolation and characterization of a mannan-binding protein from rabbit serum. Biochem Biophys Res Commun 95, 658–664 (1980).
Kozutsumi Y. , 'Isolation and characterization of a mannan-binding protein from rabbit serum ' (1980 ) 95 Biochem Biophys Res Commun : 658 -664 .
Super M et al.: Association of low levels of mannan-binding protein with a common defect of opsonisation. Lancet 2, 1236–1239 (1989).
Super M. , 'Association of low levels of mannan-binding protein with a common defect of opsonisation ' (1989 ) 2 Lancet : 1236 -1239 .
Garred P et al.: Deficiency of mannan-binding protein — a recently discovered complement defect syndrome. Ugeskr Laeger 155, 25–29 (1993).
Garred P. , 'Deficiency of mannan-binding protein — a recently discovered complement defect syndrome ' (1993 ) 155 Ugeskr Laeger : 25 -29 .
Vorup-Jensen T et al.: Distinct pathways of mannan-binding lectin (MBL)- and C1-complex autoactivation revealed by reconstitution of MBL with recombinant MBL-associated serine protease-2. J Immunol 165, 2093–2100 (2000).
Vorup-Jensen T. , 'Distinct pathways of mannan-binding lectin (MBL)- and C1-complex autoactivation revealed by reconstitution of MBL with recombinant MBL-associated serine protease-2 ' (2000 ) 165 J Immunol : 2093 -2100 .
Matsushita M et al.: Proteolytic activities of two types of mannose-binding lectin-associated serine protease. J Immunol 165, 2637–2642 (2000).
Matsushita M. , 'Proteolytic activities of two types of mannose-binding lectin-associated serine protease ' (2000 ) 165 J Immunol : 2637 -2642 .
Hajela K et al.: The biological functions of MBL-associated serine proteases (MASPs). Immunobiology 205, 467–475 (2002).
Hajela K. , 'The biological functions of MBL-associated serine proteases (MASPs) ' (2002 ) 205 Immunobiology : 467 -475 .
Dahl MR et al.: MASP-3 and its association with distinct complexes of the mannan-binding lectin complement activation pathway. Immunity 15, 127–135 (2001).
Dahl M.R. , 'MASP-3 and its association with distinct complexes of the mannan-binding lectin complement activation pathway ' (2001 ) 15 Immunity : 127 -135 .
Matsushita M et al.: Activation of the lectin complement pathway by ficolins. Int Immunopharmacol 1, 359–363 (2001).
Matsushita M. , 'Activation of the lectin complement pathway by ficolins ' (2001 ) 1 Int Immunopharmacol : 359 -363 .
Matsushita M et al.: Ficolins and the lectin complement pathway. Immunol Rev 180, 78–85 (2001).
Matsushita M. , 'Ficolins and the lectin complement pathway ' (2001 ) 180 Immunol Rev : 78 -85 .
Hansen S et al.: Collectin 11 (CL-11, CL-K1) is a MASP- 1/3-associated plasma collectin with microbial-binding activity. J Immunol 185, 6096–6104 (2010).
Hansen S. , 'Collectin 11 (CL-11, CL-K1) is a MASP- 1/3-associated plasma collectin with microbial-binding activity ' (2010 ) 185 J Immunol : 6096 -6104 .
Amara U et al.: Interaction between the coagulation and complement system. Adv Exp Med Biol 632, 71–79 (2008).
Amara U. , 'Interaction between the coagulation and complement system ' (2008 ) 632 Adv Exp Med Biol : 71 -79 .
Santizo F et al.: Lectin activity of the coagulation factor VIII/von Willebrand complex. Tohoku J Exp Med 217, 209–215 (2009).
Santizo F. , 'Lectin activity of the coagulation factor VIII/von Willebrand complex ' (2009 ) 217 Tohoku J Exp Med : 209 -215 .
Davis AE 3rd: Biological effects of C1 inhibitor. Drug News Perspect 17, 439–446 (2004).
Davis A.E. , 'Biological effects of C1 inhibitor ' (2004 ) 17 Drug News Perspect : 439 -446 .
Ikeda K et al.: C5a induces tissue factor activity on endothelial cells. Thromb Haemost 77, 394–398 (1997).
Ikeda K. , 'C5a induces tissue factor activity on endothelial cells ' (1997 ) 77 Thromb Haemost : 394 -398 .
Huber-Lang M et al.: Generation of C5a by phagocytic cells. Am J Pathol 161, 1849–1859 (2002).
Huber-Lang M. , 'Generation of C5a by phagocytic cells ' (2002 ) 161 Am J Pathol : 1849 -1859 .
Griselli M et al.: C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 190, 1733–1740 (1999).
Griselli M. , 'C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction ' (1999 ) 190 J Exp Med : 1733 -1740 .
Damman J et al.: Crosstalk between complement and Tolllike receptor activation in relation to donor brain death and renal ischemia-reperfusion injury. Am J Transplant 11, 660–669 (2011).
Damman J. , 'Crosstalk between complement and Tolllike receptor activation in relation to donor brain death and renal ischemia-reperfusion injury ' (2011 ) 11 Am J Transplant : 660 -669 .
Song WC et al.: Complement and innate immunity. Immunopharmacology 49, 187–198 (2000).
Song W.C. , 'Complement and innate immunity ' (2000 ) 49 Immunopharmacology : 187 -198 .
Koski CL et al.: Cytolysis of nucleated cells by complement: cell death displays multi-hit characteristics. Proc Natl Acad Sci U S A 80, 3816–3820 (1983).
Koski C.L. , 'Cytolysis of nucleated cells by complement: cell death displays multi-hit characteristics ' (1983 ) 80 Proc Natl Acad Sci U S A : 3816 -3820 .
Morgan BP: Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. Biochem J 264, 1–14 (1989).
Morgan B.P. , 'Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects ' (1989 ) 264 Biochem J : 1 -14 .
Tegla CA et al.: Membrane attack by complement: the assembly and biology of terminal complement complexes. Immunol Res 51, 45–60 (2011).
Tegla C.A. , 'Membrane attack by complement: the assembly and biology of terminal complement complexes ' (2011 ) 51 Immunol Res : 45 -60 .
Fosbrink M et al.: The role of c5b-9 terminal complement complex in activation of the cell cycle and transcription. Immunol Res 31, 37–46 (2005).
Fosbrink M. , 'The role of c5b-9 terminal complement complex in activation of the cell cycle and transcription ' (2005 ) 31 Immunol Res : 37 -46 .
Hugli TE: Biochemistry and biology of anaphylatoxins. Complement 3, 111–127 (1986).
Hugli T.E. , 'Biochemistry and biology of anaphylatoxins ' (1986 ) 3 Complement : 111 -127 .
Gavrilyuk V et al.: Identification of complement 5a-like receptor (C5L2) from astrocytes: characterization of antiinflammatory properties. J Neurochem 92, 1140–1149 (2005).
Gavrilyuk V. , 'Identification of complement 5a-like receptor (C5L2) from astrocytes: characterization of antiinflammatory properties ' (2005 ) 92 J Neurochem : 1140 -1149 .
de Vries B et al.: Complement factor C5a mediates renal ischemia-reperfusion injury independent from neutrophils. J Immunol 170, 3883–3889 (2003).
Vries B. , 'Complement factor C5a mediates renal ischemia-reperfusion injury independent from neutrophils ' (2003 ) 170 J Immunol : 3883 -3889 .
Chenoweth DE et al.: Demonstration of specific C5a receptor on intact human polymorphonuclear leukocytes. Proc Natl Acad Sci U S A 75, 3943–3947 (1978).
Chenoweth D.E. , 'Demonstration of specific C5a receptor on intact human polymorphonuclear leukocytes ' (1978 ) 75 Proc Natl Acad Sci U S A : 3943 -3947 .
Banz Y et al.: Role of complement and perspectives for intervention in ischemia-reperfusion damage. Ann Med 44, 205–217 (2012).
Banz Y. , 'Role of complement and perspectives for intervention in ischemia-reperfusion damage ' (2012 ) 44 Ann Med : 205 -217 .
Foreman KE et al.: C5a-induced expression of P-selectin in endothelial cells. J Clin Invest 94, 1147–1155 (1994).
Foreman K.E. , 'C5a-induced expression of P-selectin in endothelial cells ' (1994 ) 94 J Clin Invest : 1147 -1155 .
Albrecht EA et al.: C5a-induced gene expression in human umbilical vein endothelial cells. Am J Pathol 164, 849–859 (2004).
Albrecht E.A. , 'C5a-induced gene expression in human umbilical vein endothelial cells ' (2004 ) 164 Am J Pathol : 849 -859 .
Hugli TE: The structural basis for anaphylatoxin and chemotactic functions of C3a, C4a, and C5a. Crit Rev Immunol 1, 321–366 (1981).
Hugli T.E. , 'The structural basis for anaphylatoxin and chemotactic functions of C3a, C4a, and C5a ' (1981 ) 1 Crit Rev Immunol : 321 -366 .
Hugli TE: Structure and function of the anaphylatoxins. Springer Semin Immunopathol 7, 193–219 (1984).
Hugli T.E. , 'Structure and function of the anaphylatoxins ' (1984 ) 7 Springer Semin Immunopathol : 193 -219 .
Zhou W: The new face of anaphylatoxins in immune regulation. Immunobiology 217, 225–234 (2012).
Zhou W. , 'The new face of anaphylatoxins in immune regulation ' (2012 ) 217 Immunobiology : 225 -234 .
Austen WG Jr et al.: Intestinal ischemia-reperfusion injury is mediated by the membrane attack complex. Surgery 126, 343–348 (1999).
Austen W.G. , 'Intestinal ischemia-reperfusion injury is mediated by the membrane attack complex ' (1999 ) 126 Surgery : 343 -348 .
Fondevila C et al.: The membrane attack complex (C5b-9) in liver cold ischemia and reperfusion injury. Liver transpl 14, 1133–1141 (2008).
Fondevila C. , 'The membrane attack complex (C5b-9) in liver cold ischemia and reperfusion injury ' (2008 ) 14 Liver transpl : 1133 -1141 .
Walport MJ: Complement. First of two parts. N Engl J Med 344, 1058–1066 (2001).
Walport M.J. , 'Complement. First of two parts ' (2001 ) 344 N Engl J Med : 1058 -1066 .
Walport MJ: Complement. Second of two parts. N Engl J Med 344, 1140–1144 (2001).
Walport M.J. , 'Complement. Second of two parts ' (2001 ) 344 N Engl J Med : 1140 -1144 .
Nangaku M: Complement regulatory proteins in glomerular diseases. Kidney Int 54, 1419–1428 (1998).
Nangaku M. , 'Complement regulatory proteins in glomerular diseases ' (1998 ) 54 Kidney Int : 1419 -1428 .
Ahearn JM et al.: Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). Adv Immunol 46, 183–219 (1989).
Ahearn J.M. , 'Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21) ' (1989 ) 46 Adv Immunol : 183 -219 .
Miwa T et al.: Membrane complement regulatory proteins: insight from animal studies and relevance to human diseases. Int Immunopharmacol 1, 445–459 (2001).
Miwa T. , 'Membrane complement regulatory proteins: insight from animal studies and relevance to human diseases ' (2001 ) 1 Int Immunopharmacol : 445 -459 .
Miwa T et al.: Molecular cloning of rat and mouse membrane cofactor protein (MCP, CD46): preferential expression in testis and close linkage between the mouse Mcp and Cr2 genes on distal chromosome 1. Immunogenetics 48, 363–371 (1998).
Miwa T. , 'Molecular cloning of rat and mouse membrane cofactor protein (MCP, CD46): preferential expression in testis and close linkage between the mouse Mcp and Cr2 genes on distal chromosome 1 ' (1998 ) 48 Immunogenetics : 363 -371 .
Cardone J et al.: CD46 in innate and adaptive immunity: an update. Clin Exp Immunol 164, 301–311 (2011).
Cardone J. , 'CD46 in innate and adaptive immunity: an update ' (2011 ) 164 Clin Exp Immunol : 301 -311 .
Lublin DM et al.: Decay-accelerating factor: biochemistry, molecular biology, and function. Annu Rev Immunol 7, 35–58 (1989).
Lublin D.M. , 'Decay-accelerating factor: biochemistry, molecular biology, and function ' (1989 ) 7 Annu Rev Immunol : 35 -58 .
Davies A et al.: CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med 170, 637–654 (1989).
Davies A. , 'CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells ' (1989 ) 170 J Exp Med : 637 -654 .
Meri S et al.: Human protectin (CD59), an 18,000–20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 71, 1–9 (1990).
Meri S. , 'Human protectin (CD59), an 18,000–20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers ' (1990 ) 71 Immunology : 1 -9 .
Li B et al.: Mouse Crry/p65. Characterization of monoclonal antibodies and the tissue distribution of a functional homologue of human MCP and DAF. J Immunol 151, 4295–4305 (1993).
Li B. , 'Mouse Crry/p65. Characterization of monoclonal antibodies and the tissue distribution of a functional homologue of human MCP and DAF ' (1993 ) 151 J Immunol : 4295 -4305 .
Fraczek LA et al.: Transcriptional control of genes for soluble complement cascade regulatory proteins. Mol Immunol 48, 9–13 (2010).
Fraczek L.A. , 'Transcriptional control of genes for soluble complement cascade regulatory proteins ' (2010 ) 48 Mol Immunol : 9 -13 .
Vinci G et al.: In vivo biosynthesis of endogenous and of human C1 inhibitor in transgenic mice: tissue distribution and colocalization of their expression. J Immunol 169, 5948–5954 (2002).
Vinci G. , 'In vivo biosynthesis of endogenous and of human C1 inhibitor in transgenic mice: tissue distribution and colocalization of their expression ' (2002 ) 169 J Immunol : 5948 -5954 .
Ziccardi RJ: The first component of human complement (C1): activation and control. Springer Semin Immunopathol 6, 213–230 (1983).
Ziccardi R.J. , 'The first component of human complement (C1): activation and control ' (1983 ) 6 Springer Semin Immunopathol : 213 -230 .
Lappin DF et al.: Effect of interferon-gamma on complement gene expression in different cell types. Biochem J 281, 437–442 (1992).
Lappin D.F. , 'Effect of interferon-gamma on complement gene expression in different cell types ' (1992 ) 281 Biochem J : 437 -442 .
Al-Abdullah IH et al.: C1-inhibitor-biochemical properties and clinical applications. Crit Rev Immunol 5, 317–330 (1985).
Al-Abdullah I.H. , 'C1-inhibitor-biochemical properties and clinical applications ' (1985 ) 5 Crit Rev Immunol : 317 -330 .
Davis AE 3rd et al.: Biological activities of C1 inhibitor. Mol Immunol 45, 4057–4063 (2008).
Davis A.E. , 'Biological activities of C1 inhibitor ' (2008 ) 45 Mol Immunol : 4057 -4063 .
Minta JO et al.: Cloning and characterization of the promoter for the human complement factor I (C3b/C4b inactivator) gene. Gene 208, 17–24 (1998).
Minta J.O. , 'Cloning and characterization of the promoter for the human complement factor I (C3b/C4b inactivator) gene ' (1998 ) 208 Gene : 17 -24 .
Kavanagh D et al.: Membrane cofactor protein and factor I: mutations and transplantation. Semin Thromb Hemost 32, 155–159 (2006).
Kavanagh D. , 'Membrane cofactor protein and factor I: mutations and transplantation ' (2006 ) 32 Semin Thromb Hemost : 155 -159 .
Kavanagh D et al.: Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J Am Soc Nephrol 16, 2150–2155 (2005).
Kavanagh D. , 'Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome ' (2005 ) 16 J Am Soc Nephrol : 2150 -2155 .
Skattum L et al.: Complement deficiency states and associated infections. Mol Immunol 48, 1643–1655 (2011).
Skattum L. , 'Complement deficiency states and associated infections ' (2011 ) 48 Mol Immunol : 1643 -1655 .
Farries TC et al.: Competition for binding sites on C3b by CR1, CR2, MCP, factor B and Factor H. Complement Inflamm 7, 30–41 (1990).
Farries T.C. , 'Competition for binding sites on C3b by CR1, CR2, MCP, factor B and Factor H ' (1990 ) 7 Complement Inflamm : 30 -41 .
Ferreira VP et al.: Complement control protein factor H: the good, the bad, and the inadequate. Mol Immunol 47, 2187–2197 (2010).
Ferreira V.P. , 'Complement control protein factor H: the good, the bad, and the inadequate ' (2010 ) 47 Mol Immunol : 2187 -2197 .
Atkinson JP et al.: Complement factor H and the hemolytic uremic syndrome. J Exp Med 204, 1245–1248 (2007).
Atkinson J.P. , 'Complement factor H and the hemolytic uremic syndrome ' (2007 ) 204 J Exp Med : 1245 -1248 .
Lappin DF et al.: Interferon-induced transcriptional and post-transcriptional modulation of factor H and C4 binding-protein synthesis in human monocytes. Biochem J 271, 767–772 (1990).
Lappin D.F. , 'Interferon-induced transcriptional and post-transcriptional modulation of factor H and C4 binding-protein synthesis in human monocytes ' (1990 ) 271 Biochem J : 767 -772 .
Fujita T et al.: Characterization of functional properties of C4-binding protein by monoclonal antibodies. J Immunol 134, 3320–3324 (1985).
Fujita T. , 'Characterization of functional properties of C4-binding protein by monoclonal antibodies ' (1985 ) 134 J Immunol : 3320 -3324 .
Wenderfer SE et al.: Analysis of C4 and the C4 binding protein in the MRL/lpr mouse. Arthritis Res Ther 9, R114 (2007).
Wenderfer S.E. , 'Analysis of C4 and the C4 binding protein in the MRL/lpr mouse ' (2007 ) 9 Arthritis Res Ther : R114 -.
Bokisch VA et al.: Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. J Clin Invest 49, 2427–2436 (1970).
Bokisch V.A. , 'Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase ' (1970 ) 49 J Clin Invest : 2427 -2436 .
Matthews KW et al.: Carboxypeptidase N: a pleiotropic regulator of inflammation. Mol Immunol 40, 785–793 (2004).
Matthews K.W. , 'Carboxypeptidase N: a pleiotropic regulator of inflammation ' (2004 ) 40 Mol Immunol : 785 -793 .
Skidgel RA et al.: Structure and function of human plasma carboxypeptidase N, the anaphylatoxin inactivator. Int Immunopharmacol 7, 1888–1899 (2007).
Skidgel R.A. , 'Structure and function of human plasma carboxypeptidase N, the anaphylatoxin inactivator ' (2007 ) 7 Int Immunopharmacol : 1888 -1899 .